Sanofi's diabetes and cardiovascular products drastically missed their sales targets in the first quarter of the year – but the company has high hopes for its R&D pipeline this year and the spotlight is on oncology.
The French drug maker also highlighted during its April 28 earnings conference call that it is seeking asset acquisitions in...